Clinical Trials Browser

Pain, Postoperative, Pituitary Diseases

NCT07463625 2026-03-11

PiTFET

Recruiting

20 enrolled

Endocrine

Pituitary Diseases, Pituitary ACTH Hypersecretion, ACTH-Secreting Pituitary Adenoma

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Phase 2 Completed

20 enrolled

CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT04042753 2025-08-08

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Phase 2 Active not recruiting

9 enrolled

Endocrine

Pituitary Diseases, Pituitary Neoplasms

NCT06973824 2025-05-15

TYEPDD

Recruiting

1,600 enrolled

Endocrine

Pituitary Diseases, Pituitary Neoplasms

NCT06874426 2025-04-23

Endo-Olfact

Recruiting

154 enrolled

CNSEndocrine

Craniopharyngioma, Meningioma, Pituitary Diseases, Pituitary Neoplasms

Clinical Trials

POPPY

PiTFET

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

TYEPDD

Endo-Olfact